Patients receiving idelalisib versus those receiving placebo had improved rates of overall response ( 81 % vs. 13 % ; odds ratio , 29.92 ; P < 0.001 ) and overall survival at 12 months ( 92 % vs. 80 % ; hazard ratio for death , 0.28 ; P = 0.02 ) .